
|
Welcome to the:
Global Clinical Trials
Outsourcing Summit
Seoul, Korea, 14-16 May 2012
The ongoing shift of drug
development to the Asia Pacific regions continues
unabated. Whilst India, China and Japan have
become the default countries clinical development teams
are also increasingly considering other Asian Pacific
nations such as Korea, Thailand, Philippines, Malaysia
Singapore, Taiwan and Australia. Each of these countries
offers it’s own unique qualities and many factors other
than potential cost savings can effect country
selection. This may range from the indication and type
of treatment being developed, following protocols, to
the differences in medical practice standards between
East and West. It is also worth keeping in mind that,
for example, although China boasts a huge population
there is increasing competition for clinical trial
participants and smaller countries such Philippines with
relatively large populations may make patient
recruitment easier.
Cost factors have impacted on Western pharmaceutical and
Biotech companies severely over the past ten years and
have no doubt heavily influenced the move Eastwards. A
number of Asia countries can offer potential cost saving
of up 60 percent when compared to running similar trials
in the West but even in the Asia Pacific regions
questions are now being asked as to how long these cost
benefits can be maintained and it is interesting
to note that some trial costs and investigator salaries
in South Korea and Japan may even be higher than in the
West.
With so many factors to consider this poses potential
trial sponsors with numerous operational, regulatory and
logistical obstacles when deciding which countries to
conduct clinical trials in.
The Global Clinical Trials Outsourcing Summit is Global
Engage’s fourth outsourcing summit focused on the Asia
Pacific region and will provide a forum for discussion
and networking between Western and Eastern Pharma,
Biotech and CROs senior level executives. The format
will include an in depth two day conference programme
with presentations from leading industry experts as well
as interactive panel and round table discussions.
The exhibition area will allow industry suppliers to
showcase their products and services and also serve as a
networking area during refreshment breaks and lunches.
More in depth exchange of ideas will be facilitated by a
series of one-to-one meetings between delegates and
industry suppliers taking place during break out
sessions from the main conference agenda.
Some topics under discussion during the two day
conference programme will be –
• Patient access
• Patient retention
• Regulatory environment
• Intellectual property laws/practices
• Cultural concerns
• Communication and language
• Clinical trial technology
infrastructure
• Supply chain management
• Investigators' available knowledge
base
• Data standards
• Investigator standards
• Site management standards
• Anticipated costs
|
|